Researchers report that patients treated for treatment-resistant depression with esketamine NS (nasal spray), a form of ketamine, achieve better and more durable outcomes than similar patients treated with… read more.
A new study led by investigators from Mass General Brigham has found that subanesthetic intravenous ketamine was effective and not inferior to electroconvulsive therapy (ECT) for the treatment of non-psychotic,… read more.
Among patients over 60 with treatment-resistant depression, adding the antipsychotic drug aripiprazole (Abilify) to their treatment appears to be a more effective strategy than switching antidepressants. Researchers reported… read more.
Aripiprazole originally was approved by the FDA in 2002 as a treatment for schizophrenia but also has been used in lower doses as an add-on treatment for clinical… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
